Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis

Arthur E. Warrington, Kunihiko Asakura, Allan J. Bieber, Bogoljub Ciric, Virginia Van Keulen, Srini V. Kaveri, Robert A. Kyle, Larry R Pease, Moses Rodriguez

Research output: Contribution to journalArticle

209 Citations (Scopus)

Abstract

Promoting remyelination, a major goal of an effective treatment for demyelinating diseases, has the potential to protect vulnerable axons, increase conduction velocity, and improve neurologic deficits. Strategies to promote remyelination have focused on transplanting oligodendrocytes (OLs) or recruiting endogenous myelinating cells with trophic factors. Ig-based therapies, routinely used to treat a variety of neurological and autoimmune diseases, underlie our approach to enhance remyelination. We isolated two human mAbs directed against OL surface antigens that promoted significant remyelination in a virus-mediated model of multiple sclerosis. Four additional OL-binding human mAbs did not promote remyelination. Both human mAbs were as effective as human i.v. Ig, a treatment shown to have efficacy in multiple sclerosis, and bound to the surface of human OLs suggesting a direct effect of the mAbs on the cells responsible for myelination. Alternatively, targeting human mAbs to areas of central nervous system (CNS) pathology may facilitate the opsonization of myelin debris, allowing repair to proceed. Human mAbs were isolated from the sera of individuals with a form of monoclonal gammopathy. These individuals carry a high level of monoclonal protein in their blood without detriment, lending support to the belief that administration of these mAbs as a therapy would be safe. Our results are (i) consistent with the hypothesis that CNS-reactive mAbs, part of the normal Ig repertoire in humans, may help repair and protect the CNS from pathogenic immune injury, and (ii) further challenge the premise that Abs that bind OLs are necessarily pathogenic.

Original languageEnglish (US)
Pages (from-to)6820-6825
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume97
Issue number12
DOIs
StatePublished - Jun 6 2000

Fingerprint

Oligodendroglia
Multiple Sclerosis
Monoclonal Antibodies
Central Nervous System
Paraproteinemias
Demyelinating Diseases
Surface Antigens
Myelin Sheath
Neurologic Manifestations
Autoimmune Diseases
Axons
Pathology
Viruses
Wounds and Injuries
Therapeutics
Serum

ASJC Scopus subject areas

  • General
  • Genetics

Cite this

Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. / Warrington, Arthur E.; Asakura, Kunihiko; Bieber, Allan J.; Ciric, Bogoljub; Van Keulen, Virginia; Kaveri, Srini V.; Kyle, Robert A.; Pease, Larry R; Rodriguez, Moses.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 97, No. 12, 06.06.2000, p. 6820-6825.

Research output: Contribution to journalArticle

Warrington, Arthur E. ; Asakura, Kunihiko ; Bieber, Allan J. ; Ciric, Bogoljub ; Van Keulen, Virginia ; Kaveri, Srini V. ; Kyle, Robert A. ; Pease, Larry R ; Rodriguez, Moses. / Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. In: Proceedings of the National Academy of Sciences of the United States of America. 2000 ; Vol. 97, No. 12. pp. 6820-6825.
@article{43df02892d1a491aacb2da88ab685b84,
title = "Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis",
abstract = "Promoting remyelination, a major goal of an effective treatment for demyelinating diseases, has the potential to protect vulnerable axons, increase conduction velocity, and improve neurologic deficits. Strategies to promote remyelination have focused on transplanting oligodendrocytes (OLs) or recruiting endogenous myelinating cells with trophic factors. Ig-based therapies, routinely used to treat a variety of neurological and autoimmune diseases, underlie our approach to enhance remyelination. We isolated two human mAbs directed against OL surface antigens that promoted significant remyelination in a virus-mediated model of multiple sclerosis. Four additional OL-binding human mAbs did not promote remyelination. Both human mAbs were as effective as human i.v. Ig, a treatment shown to have efficacy in multiple sclerosis, and bound to the surface of human OLs suggesting a direct effect of the mAbs on the cells responsible for myelination. Alternatively, targeting human mAbs to areas of central nervous system (CNS) pathology may facilitate the opsonization of myelin debris, allowing repair to proceed. Human mAbs were isolated from the sera of individuals with a form of monoclonal gammopathy. These individuals carry a high level of monoclonal protein in their blood without detriment, lending support to the belief that administration of these mAbs as a therapy would be safe. Our results are (i) consistent with the hypothesis that CNS-reactive mAbs, part of the normal Ig repertoire in humans, may help repair and protect the CNS from pathogenic immune injury, and (ii) further challenge the premise that Abs that bind OLs are necessarily pathogenic.",
author = "Warrington, {Arthur E.} and Kunihiko Asakura and Bieber, {Allan J.} and Bogoljub Ciric and {Van Keulen}, Virginia and Kaveri, {Srini V.} and Kyle, {Robert A.} and Pease, {Larry R} and Moses Rodriguez",
year = "2000",
month = "6",
day = "6",
doi = "10.1073/pnas.97.12.6820",
language = "English (US)",
volume = "97",
pages = "6820--6825",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "12",

}

TY - JOUR

T1 - Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis

AU - Warrington, Arthur E.

AU - Asakura, Kunihiko

AU - Bieber, Allan J.

AU - Ciric, Bogoljub

AU - Van Keulen, Virginia

AU - Kaveri, Srini V.

AU - Kyle, Robert A.

AU - Pease, Larry R

AU - Rodriguez, Moses

PY - 2000/6/6

Y1 - 2000/6/6

N2 - Promoting remyelination, a major goal of an effective treatment for demyelinating diseases, has the potential to protect vulnerable axons, increase conduction velocity, and improve neurologic deficits. Strategies to promote remyelination have focused on transplanting oligodendrocytes (OLs) or recruiting endogenous myelinating cells with trophic factors. Ig-based therapies, routinely used to treat a variety of neurological and autoimmune diseases, underlie our approach to enhance remyelination. We isolated two human mAbs directed against OL surface antigens that promoted significant remyelination in a virus-mediated model of multiple sclerosis. Four additional OL-binding human mAbs did not promote remyelination. Both human mAbs were as effective as human i.v. Ig, a treatment shown to have efficacy in multiple sclerosis, and bound to the surface of human OLs suggesting a direct effect of the mAbs on the cells responsible for myelination. Alternatively, targeting human mAbs to areas of central nervous system (CNS) pathology may facilitate the opsonization of myelin debris, allowing repair to proceed. Human mAbs were isolated from the sera of individuals with a form of monoclonal gammopathy. These individuals carry a high level of monoclonal protein in their blood without detriment, lending support to the belief that administration of these mAbs as a therapy would be safe. Our results are (i) consistent with the hypothesis that CNS-reactive mAbs, part of the normal Ig repertoire in humans, may help repair and protect the CNS from pathogenic immune injury, and (ii) further challenge the premise that Abs that bind OLs are necessarily pathogenic.

AB - Promoting remyelination, a major goal of an effective treatment for demyelinating diseases, has the potential to protect vulnerable axons, increase conduction velocity, and improve neurologic deficits. Strategies to promote remyelination have focused on transplanting oligodendrocytes (OLs) or recruiting endogenous myelinating cells with trophic factors. Ig-based therapies, routinely used to treat a variety of neurological and autoimmune diseases, underlie our approach to enhance remyelination. We isolated two human mAbs directed against OL surface antigens that promoted significant remyelination in a virus-mediated model of multiple sclerosis. Four additional OL-binding human mAbs did not promote remyelination. Both human mAbs were as effective as human i.v. Ig, a treatment shown to have efficacy in multiple sclerosis, and bound to the surface of human OLs suggesting a direct effect of the mAbs on the cells responsible for myelination. Alternatively, targeting human mAbs to areas of central nervous system (CNS) pathology may facilitate the opsonization of myelin debris, allowing repair to proceed. Human mAbs were isolated from the sera of individuals with a form of monoclonal gammopathy. These individuals carry a high level of monoclonal protein in their blood without detriment, lending support to the belief that administration of these mAbs as a therapy would be safe. Our results are (i) consistent with the hypothesis that CNS-reactive mAbs, part of the normal Ig repertoire in humans, may help repair and protect the CNS from pathogenic immune injury, and (ii) further challenge the premise that Abs that bind OLs are necessarily pathogenic.

UR - http://www.scopus.com/inward/record.url?scp=0034612279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034612279&partnerID=8YFLogxK

U2 - 10.1073/pnas.97.12.6820

DO - 10.1073/pnas.97.12.6820

M3 - Article

C2 - 10841576

AN - SCOPUS:0034612279

VL - 97

SP - 6820

EP - 6825

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 12

ER -